Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 85,947 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Peripheral Arterial Disease
Interventions: Evolocumab; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Atrial Fibrillation and Flutter
Interventions: Cardiac ablation via catheter; Device
Lead sponsor: EPD Solutions, A Philips Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Immune Deficiency, Metabolic Syndrome
Interventions: Influenza vaccine; Biological
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Elvucitabine, Lamivudine; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 8
States / cities: Birmingham, Alabama • Sacramento, California • Miami, Florida + 5 more

Conditions: Osteoporosis
Interventions: phylloquinone (K1), menatetranone (MK4); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Female only
Enrollment: 375 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Stones
Interventions: ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 19 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 11
States / cities: Scottsdale, Arizona • San Diego, California • Baltimore, Maryland + 8 more

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 10
States / cities: Anaheim, California • Coronado, California • San Jose, California + 7 more

Conditions: Kaposi's Sarcoma, HHV-8, KSHV
Interventions: BAY 43-9006; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hemoglobinuria, Paroxysmal, Non-Hodgkin Lymphoma
Interventions: Allogeneic Stem Cell Transplantation, Chemotherapy and antibodies; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Healthy
Interventions: PF-04634817 Placebo, PF-04634817; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Myopia
Interventions: Bromfenac; Drug
Lead sponsor: Virdi Eye Clinic; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rock Island, Illinois

Conditions: Gastrointestinal Stromal Tumors
Interventions: Masitinib, Sunitinib; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Epilepsy
Interventions: lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 29 more

Conditions: Healthy Volunteers
Interventions: INCB057643; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: BLU-782, Placebo, BLU-782 taken with food; Drug
Lead sponsor: Blueprint Medicines Corporation; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Interventions: Dapansutrile, Placebo Tablet; Drug · Other
Lead sponsor: Olatec Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 21 more

Conditions: Heart Failure
Interventions: LMI 1195; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
Interventions: Temsirolimus, Etoposide, Cyclophosphamide, Methotrexate, Hydrocortisone, Cytarabine; Drug
Lead sponsor: Therapeutic Advances in Childhood Leukemia Consortium; Other
Eligibility: 1 Year to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 25
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 22 more

Conditions: Myofascial Trigger Point Pain, Myofacial Pain
Interventions: Trigger point injection with 1% lidocaine, Lidocaine patch 5%; Procedure · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orange, California

Conditions: Caregivers, Community Health Workers, Knowledge, Attitude, Self-Efficacy, Intentions, Health
Interventions: Intervention to Help Orient Men to Excel (IN-HOME), Supplying Useful Perimenopause Through Post-menopause Online Resources and Tools (SUPPORT); Behavioral · Other
Lead sponsor: KDH Research & Communication; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Substance Related Disorder, Nicotine Dependence
Interventions: Nicotine; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson's Disease
Interventions: Donepezil; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 30 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Acne Scars
Interventions: Venus Viva; Device
Lead sponsor: Venus Concept; Industry
Eligibility: 22 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Paclitaxel, trastuzumab, Neratinib; Drug · Biological
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Pittsburgh, Pennsylvania • Morgantown, West Virginia

Search by objective public record fields.

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

Dielectric Tissue Imaging in Cavotricuspid Isthmus Ablation

Impact of Metabolic Syndrome on Flu Vaccine Efficacy

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

Vitamin K and Bone Turnover in Postmenopausal Women

Struvite Stones Antibiotic Study

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

Stem Cell Transplantation for Patients With Hematologic Malignancies

First In Human Study Of Increasing Oral Doses Of PF-04634817

Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Pediatric Epilepsy Trial in Subjects 1-24 Months

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

Intervention to Help Orient Men to Excel (IN-HOME) Phase II Study

Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers

Effects of Cholinergic Augmentation on Measures of Balance and Gait

Clinical Evaluation of Fractional Radiofrequency for the Treatment Acne Scarring

Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer